Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Abcellera Biologics Inc.
Headquarters: Vancouver, BC, Canada
Website: http://www.abcellera.com
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Carl Lars G. Hansen, PhD
Number Of Employees: 596
Enterprise Value: $275,029,669
PE Ratio: -4.18
Exchange/Ticker 1: NASDAQ:ABCL
Exchange/Ticker 2: N/A
Latest Market Cap: $703,251,712
BioCentury | Aug 6, 2024
Deals
Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | May 2, 2024
Finance
Venture report: Rounds for psychedelic play Reunion, cancer company Delphia
Plus: Syndicate backs BridgeBio’s cancer spinout, AbCellera teams with investors to form asset-focused newcos, and more
BioCentury | Mar 30, 2024
Discovery & Translation
Combining ADCs with protein degraders could widen the therapeutic windows of both
Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge
BioCentury | Mar 12, 2024
Deals
Deal report: Boehringer-Sosei pursuing new schizophrenia target
Plus: Gilead- Merus to develop trispecific T cell engagers for cancer, and Armatus-Solid collab
BioCentury | Sep 6, 2023
Management Tracks
Thaysen leaving Agilent to become CEO of Illumina
Plus: Josh Schimmer, Eric Schmidt join Cantor
BioCentury | Apr 20, 2023
Emerging Company Profile
Abdera: optimizing tunable radiotherapeutics for safety
Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues
BioCentury | Mar 10, 2023
Guest Commentary
Pioneering for patients: biotechs’ role in accelerating global innovation
Platform technologies, AI and global clinical trials offer different but synergistic angles on reducing cycle time for drug development
BioCentury | Mar 1, 2023
Emerging Company Profile
Tachyon’s VC round, CIRM grant drive first-in-class oncology program to clinic
Team including Quanticel co-founders has begun Phase I testing of KDM4 program that had traveled through Celgene, BMS
BioCentury | Jan 26, 2023
Management Tracks
Juvena hires three new senior executives
Plus: new CEO at ClostraBio, and updates from Cambrian and Pliant
BioCentury | Dec 1, 2022
Deals
AbCellera, Rallybio partnering on rare disease mABS
Deal extends AbCellera’s partnership streak
Items per page:
1 - 10 of 146